Replies to post #15378 on Avid Bioservices Inc (CDMO)

[jazzbeerman]

toolong,


I think PPHM's anti-phospholipid platform (actually I suppose I should call it phospholipid-targeting platform, since it goes beyond antibodies), will spawn many drugs.

We should see

* humanized bavi- ( could be called Bavituzumab, or Bavitumumab)

* Bavi with any number of other agents attached. There's alredy several preclinical studies...

* anti-phosphatidylethanolamine (anti-PE) mabs

* PE binding peptides, (made from duramycin conjugates that have been tweaked to be too big/unable to enter through cells)

* PS binding peptides - (possibly derrived from domain V of Beta-2-glycoprotein I)

* "Betabodies"

* "Receptorbodies"

etc, etc, etc.....




and I'd think that - if the bavi phase 2 trials go well, the "phospholipid-targeting" space will get busy. Who knows how it'll all play out, but it looks very very prommising.

It turns out that immune cells clearing apoptotic cells is an actively immunosuppressive process, a big surprise, and that is a BIG insight into why the diseases that get the best of us, - get the best of us! It's that big IMO. It comes down to the facts that any successful multicellular organism has necessarily developed different ways to deal with disposal of native cells (Peter Henson has coined a new word for this - "efferocytosis" from "effero" - "to carry to the grave") as opposed to dealing with pathogenic invaders. As a result of this necessary difference in our immune response, evolution has favored pathogenesis that resembles apoptosis....

I guess it's obvious how important I think the PS-targeting platform is :)



j